The results of home DNA testing company 23AndMe will be used by pharmaceutical giant GlaxoSmithKline to design new drugs, NBC News reports.

The details: 23AndMe users were allowed to opt out of research, NBC reports. The first goal is to design a new drug to treat Parkinson's disease by looking at a gene called LRRK2. 23AndMe CEO Anne Wojcicki said in a blog post about the companies' collaboration: "By working with GSK, we believe we will accelerate the development of breakthroughs."